araag2/HINT huggingface dataset:
Clinical trial NCT01049217 (phase 3, status: terminated)
Conditions: neuropathy
ICD codes: G58.0, G61.1, A52.15, G60.3, G61.82, H46.2, H46.3
Drugs: pregabalin, placebo
SMILES: NCC1(CC(O)=O)CCCCC1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    see termination reason in detailed description.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Men and women, ages of 18 or greater

          -  Documented evidence of HIV-1 infection

          -  Documented diagnosis of HIV-associated Distal Symmetrical Polyneuropathy (DSP) with
             subjective sensory symptom of pain

          -  Pain starts in the feet

        Exclusion Criteria:

          -  Subject has untreated vitamin B12 deficiency (serum B12 level <200 pg/ml) or if
             treated B12 deficiency -treatment is less than 6 months of B12 supplementation
             (injection or intranasal B12) prior to screening

          -  Diabetes mellitus requiring regular medical treatment (other than diet and exercise)
             or HbA1C >6.9

          -  Subjects with peripheral neuropathic pain that is not associated with HIV infection;
             including subjects with conditions such as: Post Herpetic Neuralgia (PHN), Diabetic
             Peripheral Neuropathy (DPN), familial neuropathies; compression related neuropathy,
             radicular pain, other infection related neuropathies (eg, leprosy); neuropathy related
             to: metabolic abnormalities; nutritional factors; vascular insults; inflammation;
             autoimmune disease; and malignancy
Clinical trial NCT01474538 (phase 3, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: insulin lispro, insulin aspart
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Have type 2 diabetes (per World Health Organization [WHO] Classification of Diabetes)

          -  Have been treated with CSII therapy using a rapid-acting analog for the previous 6
             months

          -  Have a screening A1C less than or equal to 9.0% (no lower limit for A1C)

          -  Have a body mass index (BMI) less than 45 kilograms/square meter (kg/m²) at screening

          -  Have a history of stable body weight (not varying by greater than 10% for at least 3
             months prior to screening)

          -  For participants on oral anti-diabetes medications (OAMs): must have been on a stable
             dose of OAMs, labeled for use with insulin, for at least 3 months prior to study entry

        Exclusion Criteria:

          -  Have severe insulin resistance [require greater than 2 units/kilogram/day (U/kg/day)
             of insulin]

          -  Are taking or have taken within the last 3 months, antihyperglycemic medication not
             approved for use with insulin, injectable non-insulin antihyperglycemic medications,
             or have a contraindication to current antihyperglycemic medication

          -  Have a serum creatinine greater than or equal to 2 milligrams/deciliter (mg/dL) if not
             on metformin; known metabolic or lactic acidosis; any condition associated with
             hypoperfusion, hypoxemia, dehydration, or sepsis; and/or a radiologic contrast study
             within 48 hours prior to study entry

          -  Are receiving chronic (lasting longer than 2 weeks) systemic glucocorticoid therapy
             (excluding topical, intraocular, intraarticular, and inhaled preparations) or have
             received such therapy within 2 weeks immediately before screening

          -  Have had more than 1 episode of hypoglycemia (defined as requiring assistance of a
             third party due to disabling hypoglycemia) within 6 months prior to entry into the
             study
Clinical trial NCT00596830 (phase 3, status: terminated)
Conditions: carcinoma, squamous cell, carcinoma, adenosquamous, carcinoma, large cell, carcinoma, non-small-cell lung
ICD codes: C44.520, C44.92, C44.02, C44.321, C44.521, C44.82, C44.42, C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31, C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, C4A.8, D02.20, D02.21, D02.22
Drugs: cp-751,871 (figitumumab), carboplatin, paclitaxel, carboplatin, paclitaxel
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, N[C@@H](CCCNC(N)=N)C(O)=O, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC
Reason stopped: 
    see termination reason in detailed description.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Confirmed diagnosis of non small cell lung cancer with a primary histology of
             predominantly squamous cell, large cell or adenosquamous carcinoma.

          -  Advanced NSCLC with documented Stage IIIB (with pleural effusion) or Stage IV or
             recurrent disease.

          -  No prior systemic treatment for NSCLC, except for adjuvant chemotherapy. Adjuvant
             chemotherapy must have completed for greater than or equal to 12 months prior to
             randomization.

          -  Prior surgery or radiation therapy is permitted if completed at least 3 weeks prior to
             randomization and all acute toxicities have resolved.

          -  ECOG performance status (PS) 0 or 1.

        Exclusion Criteria:

          -  Patients with symptomatic central nervous system (CNS) metastases are not permitted.

          -  Patients requiring chronic steroid use or patients with uncontrolled diabetes are not
             permitted.

          -  Patients with other active cancer types are not permitted.
Clinical trial NCT00076232 (phase 3, status: completed)
Conditions: hiv infections, hiv seronegativity, herpes genitalis
ICD codes: Z21
Drugs: acyclovir, acyclovir placebo
SMILES: NC1=NC(=O)C2=C(N1)N(COCCO)C=N2, NC1=NC(=O)C2=C(N1)N(COCCO)C=N2
Eligibility criteria:

        Inclusion Criteria For All Participants:

          -  HIV-uninfected

          -  HSV-2 infected

          -  Plans to stay in the area for the duration of study participation

          -  Willing and able to provide consent, undergo clinical evaluations, take study drugs,
             adhere to follow-up schedule, and provide adequate locator information

        Inclusion Criteria for MSM:

          -  At least 1 episode of anal intercourse with another man within 6 months of study entry

        Inclusion Criteria for WSM:

          -  At least 1 episode of unprotected vaginal sex within 6 months of study entry

        Exclusion Criteria For All Participants:

          -  Current enrollment in another HIV vaccine or prevention trial

          -  History of adverse reaction to acyclovir

          -  Current or planned use of famiciclovir, valacyclovir, or acyclovir for genital HSV.
             Use of short-course antiviral therapy for herpes zoster after enrollment is allowed.

          -  Known plans for travel away from study site for more than 2 months

        Exclusion Criteria for MSM:

          -  In a mutually monogamous relationship with an HIV uninfected partner throughout the
             past 2 years

          -  Reported sex at birth as female

        Exclusion Criteria for WSM:

          -  Pregnancy at screening or enrollment
Clinical trial NCT01097330 (phase 3, status: terminated)
Conditions: defibrillators, implantable, tachycardia, ventricular
ICD codes: I47.2
Drugs: amiodarone
SMILES: CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=C(O1)C=CC=C2
Reason stopped: 
    anticipated non-feasibility of recruitment objectives
  
Eligibility criteria:

        Inclusion Criteria - Patients must meet all of the following criteria:

          -  > 18 and < 85 years of age

          -  ICD implanted for primary prophylaxis against sudden cardiac death or ICD implanted
             for secondary prophylaxis against spontaneous or inducible sustained VT without any
             reversible causes

          -  Coronary artery disease (CAD) with prior myocardial infarction (MI)

          -  ICD or electrocardiogram (ECG) documentation of ventricular arrhythmia responsible for
             appropriate ICD therapy [antitachycardia pacing (ATP) & shocks].

        Exclusion Criteria - Patients should not have any of the following criteria:

          -  Contraindication or allergy to contrast media, routine procedural medications or
             catheter materials

          -  Contraindication to an interventional procedure

          -  Current or previous (within 3 months) amiodarone therapy

          -  Atrial Fibrillation requiring antiarrhythmic drug therapy

          -  Contraindication to amiodarone therapy

          -  New York Heart Association (NYHA) functional class IV

          -  Myocardial infarction within the past 60 days

          -  Stroke within the past 90 days

          -  Unstable angina

          -  Hypertrophic cardiomyopathy, Non-ischemic dilated cardiomyopathy, Arrhythmogenic Right
             Ventricular Dysplasia, Brugada Syndrome, Catecholamine sensitive polymorphic VT or
             long QT syndrome

          -  Patients with active ischemia that are eligible for revascularization

          -  Life expectancy less than 6 months

          -  Incessant or multiple episodes of VT requiring immediate therapy with medications or
             ablation

          -  Untreated hypothyroidism or hyperthyroidism. Patients who are euthyroid on thyroid
             hormone replacement therapy are acceptable.

          -  Current enrollment in another investigational drug or device study.

          -  Presence of any other condition that the investigator feels would be problematic or
             would restrict or limit the participation of the patient for the entire study period.

          -  Absolute contra-indication to the use of heparin and or warfarin.

          -  Documented intra-atrial thrombus, ventricular thrombus (< 6 months after detection of
             thrombus), tumor, or another abnormality which precludes catheter introduction.

          -  Females of childbearing potential who are not practicing protocol acceptable method of
             birth control.
Clinical trial NCT00435162 (phase 3, status: completed)
Conditions: hypertension
ICD codes: I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10
Drugs: valsartan 0.25 mg/kg, valsartan 1.0 mg/kg, valsartan 4.0 mg/kg
SMILES: CCCCC(=O)N(CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1)[C@@H](C(C)C)C(O)=O, CCCCC(=O)N(CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1)[C@@H](C(C)C)C(O)=O, CCCCC(=O)N(CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1)[C@@H](C(C)C)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Children aged 6 months - 5 years at Visit 1, with a documented history of hypertension

          -  Must be able to swallow liquid formulation

          -  Must be ≥ 6 kg or ≤ 40 kg at randomization

          -  Must have documented history MSSBP (mean of 3 measurements) must be ≥ 95th percentile
             for age, gender and height, at randomization

          -  If patients enter with uncontrolled BP they can remain on background antihypertensives
             with an unchanged dosing regimen

          -  If patients have had a solid organ transplant more than 1 year ago they must be on
             stable doses of immunosuppressive therapy

          -  Parent(s)/guardian(s) are able to follow verbal and/or written instructions in the
             local language

        Exclusion Criteria:

          -  Patients with background ARB therapy

          -  Patients demonstrating any clinically significant abnormalities or clinically
             noteworthy abnormal lab values (other than those relating to renal function)

          -  AST/SGOT or ALT/SGPT > 3 times the upper limit of the reference range

          -  Glomerular filtration rate < 30 mL/min/1.73m²

          -  Serum potassium > upper limit of the reference range

          -  MSSBP ≥ 25% above the 95th percentile

          -  Patients exhibiting clinically significant ECG abnormalities

          -  Patients that have coarctation of the aorta with a gradient of ≥ 30 mm Hg, or renal
             artery stenosis

        Other protocol-defined inclusion/exclusion criteria may apply
Clinical trial NCT00185159 (phase 3, status: completed)
Conditions: diabetes mellitus, type 2, cardiovascular disease, kidney disease
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44, A52.00, A52.09, A50.54, Z01.810, Q87.418, Z13.6, R94.30, I12.9, N18.9, Q61.9, I12.0, D63.1, N18.1, N18.5
Drugs: olmesartan medoxomil, placebo tablets
SMILES: CCCC1=NC(=C(N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1)C(O)=O)C(C)(C)O, NC[C@H]1CC[C@@H](CC1)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diabetes mellitus type 2, defined as fasting blood glucose of greater than or equal to
             126 mg/dL;

          -  Presence of at least one of the following cardiovascular risk factors:

               1. total cholesterol greater than 200 mg/dL or statin treatment,

               2. High density lipoprotein (HDL) less than 40 mg/dL,

               3. triglycerides greater than 150 mg/dL and less than 400 mg/dL,

               4. blood pressure greater than or equal to 130/80 mmHg,

               5. Body mass index (BMI) greater than 28 kg/m2,

               6. waist circumference greater than 102 cm for men and greater than 88 cm for women,

               7. smoking of more than 5 cigarettes a day;

          -  Normoalbuminuria at screening

        Exclusion Criteria:

          -  Severe uncontrolled hyperlipidemia;

          -  Documented renal and/or renal-vascular disease;

          -  Myocardial infarction, stroke or myocardial revascularization within the last 6
             months;

          -  History of alcohol and/or drug abuse;

          -  Allergic reaction, lack of response or contraindication to angiotensin receptor
             blockers (ARBs);

          -  Current treatment with an ARB or angiotensin converting enzyme (ACE) inhibitor
Clinical trial NCT00616993 (phase 3, status: completed)
Conditions: inflammation
ICD codes: H01.9, H30.93, H05.00, H30.003, H30.013, H30.033, H30.103
Drugs: difluprednate
SMILES: [H][C@@]12CC[C@](OC(=O)CCC)(C(=O)COC(C)=O)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C
Eligibility criteria:

        Inclusion Criteria:

          -  Scheduled for unilateral ocular surgery.

        Exclusion Criteria:

          -  Systemic administration of any corticosteroid or immunosuppressive drug in the 2 weeks
             prior to study enrollment.
Clinical trial NCT01015456 (phase 3, status: terminated)
Conditions: lupus nephritis
ICD codes: B26.83, A51.44, N11.8, N11.9, N12
Drugs: mycophenolate sodium, cyclophosphamide
SMILES: COC1=C(C\C=C(/C)CCC(O)=O)C(O)=C2C(=O)OCC2=C1C, ClCCN(CCCl)P1(=O)NCCCO1
Reason stopped: 
    data safety monitoring board concerning of the participants' safety
  
Eligibility criteria:

        Inclusion Criteria:

          -  age 16 years of above at the time of screening

          -  ability and willingness to provide written informed consent (or to obtain consent from
             parent guardian where applicable) and to comply with the schedule of protocol
             requirements

          -  Diagnosis of SLE according to ACR criteria. At least 4 criteria must have been present
             for the diagnosis of SLE. The 4 criteria do not have to be present at the time of
             screening

          -  Active lupus nephritis defined as follows: Biopsy proven (within 16 weeks prior to
             screening) ISN Class III or IV (A or A/C) not include III(C) IV(C) and VI (>90%
             chronic irreversible scarring)

          -  Relapse or resistant to (3 consecutive doses) IVCY

          -  Resistant lupus or Relapse lupus nephritis defined as follows:

               -  Increase in serum creatinine >/= 0.3 mg/dl or

               -  Increase in proteinuria > 1.5 g/day (which must have improved by ≥ 50% in the
                  preceding 3 months)

          -  Life-time cumulative dose of IVCY > 6 grams

          -  Female patients of childbearing potential must have a negative serum pregnancy

        Exclusion Criteria:

        Relates to SLE

          -  Diagnosis of rapid progressive glomerulonephritis (RPGN): doubling serum creatinine
             and/or crescentic glomeruli ≥ 30%

          -  Severe renal impairment as defined by calculated creatinine clearance or MDRD-GFR < 30
             ml/min(except creatinine clearance or MDRD-GFR > 50 ml/min in the 12 weeks prior to
             screening)

          -  History of serious disease or complication in any organ system that not appropriate to
             treatment immunosuppressive drug groups.

          -  Severe extra-renal organ involvement

        Related to Treatment

          -  Previous of any Mycophenolate groups in the 6 months prior to screening

          -  Treatment with any investigational drugs in the 3 months prior to screening

        Related to General Health

          -  Pregnancy or breast feeding mothers.

          -  Concomitant condition which has required treatment moderate to high dose steroid in
             the 12 weeks prior to screening.

          -  Evidence of significant uncontrolled concomitant disease in any organ system not
             related to SLE.

          -  History of cancer, including solid tumors, hematological malignancies and carcinoma.

          -  Evidence of current abuse of drugs or alcohol.

        Related to Laboratory Findings

          -  Neutrophile < 1,500/mm3, Hb < 7g/L, Platelet < 50,000/mm3 (except active SLE)

          -  Positive HBsAg or anti-HCV or anti-HIV.
Clinical trial NCT00275275 (phase 3, status: completed)
Conditions: parkinson disease
ICD codes: G20
Drugs: requip pr, mirapex
SMILES: CCCN[C@H]1CCC2=C(C1)SC(N)=N2
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of Parkinson Disease

          -  Currently taking pramipexole

          -  Never have taken Requip CR

        Exclusion Criteria:

          -  Can not have significant adverse effects to standard Requip

          -  Can not have atypical PD due to drugs, metabolic disorders, encephalitis or
             degenerative diseases

          -  Can not have unstable medical conditions

          -  Can not be taking concurrent monoamine oxidase inhibitors except for selegiline (10mg
             per day or less)

          -  Female patients of childbearing potential must be using an effective method of
             contraception.

          -  Can not be pregnant or lactating.

        This may not be a complete list; there may be additional criteria which may apply.
Clinical trial NCT00391274 (phase 3, status: completed)
Conditions: non-small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: pemetrexed, docetaxel
SMILES: [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H], [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Histologic or cytologic diagnosis NSCLC (Stage IIIA, IIIB, or IV), not amenable to
             curative surgery or radiotherapy

          -  At least one prior chemotherapy for palliative therapy

          -  Response Evaluation Criteria In Solid Tumors (RECIST) criteria for disease status
             assessment

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2

        Exclusion Criteria:

          -  Concurrent administration of any other tumor therapy

          -  Pregnant or breast feeding

          -  Serious concomitant disorders

          -  Inability or unwillingness to take folic acid or vitamin B12 supplementation
Clinical trial NCT00422149 (phase 3, status: completed)
Conditions: rhinitis, allergic, seasonal, conjunctivitis, allergic
ICD codes: J30.2
Drugs: sublivac® grasses/placebo treatment, sublivac® grasses treatment, placebo treatment
SMILES: COC1=CC=CC=C1OC1=C(NS(=O)(=O)C2=CC=C(C=C2)C(C)(C)C)N=C(N=C1OCCO)C1=NC=CC=N1, COC1=CC=CC=C1OC1=C(NS(=O)(=O)C2=CC=C(C=C2)C(C)(C)C)N=C(N=C1OCCO)C1=NC=CC=N1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects with allergic rhinoconjunctivitis with or without mild asthma FEV1 ≥ 70%) for
             at least 2 years. Their allergic symptoms should be related to grass pollen Use of
             anti-allergy symptomatic medication in the last pollen season (or, in case of a low
             pollen season, in one of the two previous years)

          -  A positive skin prick test (>3 mm) for early flowering treesgrasses and specific serum
             IgE-test(>1 U/ml) for grass pollen (Lolium perenne, Phleum pratense and Poa
             pratensis).

        Exclusion Criteria:

          -  A positive SPT for perennial allergens of house dust mite

          -  Allergy to any of the excipients

          -  Symptoms related to concomitant sensitisation to perennial allergens of pets

          -  Chronic asthma or emphysema, particularly with a FEV1 < 70 % of predicted value or use
             of inhalation corticosteroids outside grass and tree pollen season for more than two
             episodes and/or longer than fourteen days

          -  Use of symptomatic medication for more than three episodes and/or longer than three
             days outside the tree- or grass pollen season

          -  Serious immuno-pathological diseases or malignancies (including auto-immune diseases,
             tuberculosis, HIV)

          -  Inflammation and infection of the target organ

          -  Severe atopic dermatitis requiring systemic immuno-suppressive medication

          -  Allergen specific immuno-therapy treatment within the last 5 years for a period longer
             than three months

          -  History of life threatening anaphylactic events, including anaphylactic food allergy,
             insect venom anaphylaxis, exercise or drug induced anaphylaxis

          -  A positive pregnancy test, lactation or inadequate contraceptive measures Alcohol- or
             drug abuse

          -  Lack of co-operation or severe psychological disorders